PXSP.L
現在値
0.70GBp変化
0.03(+3.70%)出来高
157,331本日のレンジ
-
--52週レンジ
-
1.15∙ 約20分前の相場を表示しています。
前日終値 | 0.68 |
|---|---|
始値 | 0.00 |
出来高 | 157,331 |
3か月平均出来高 | 18.60 |
高値 | -- |
安値 | -- |
52週高値 | 1.15 |
52週安値 | 0.65 |
発行済株式数 | 2,210.82 |
時価総額 | 14.97 |
予想PER | -- |
配当利回り | -- |
Provexis Signs Two New Agreements With DSM
Provexis FY Underlying Operating Loss Narrows
Provexis H1 Underlying Operating Loss 95,000 Stg
Provexis plc is a United Kingdom-based company, which is engaged in commercializing the Fruitflow anti-thrombotic technology. Fruitflow is a patented natural ingredient, which helps with platelet aggregation. Fruitflow has been shown in human trials to reduce the propensity for aberrant blood clotting, typically associated with cardiovascular disease, which can lead to heart attack and stroke. The extract is available in two formats, a syrup and a powder, and it can be included in a range of food, beverage and dietary supplement formats. Fruitflow is a concentrated form of bioactive, which is lycopene-free and contains approximately 30 anti-platelet compounds. The Company also offers Fruitflow+ Omega-3 dietary supplement products, which are available to purchase from the Company’s Website, e-commerce Website www.fruitflowplus.com. The Company’s subsidiaries include Provexis Nutrition Limited (PNL) and Provexis Natural Products Limited (PNP).
業種
Biotechnology & Drugs
エグゼクティブリーダーシップ
C. Dawson Buck
Non-Executive Independent Chairman of the Board
Niamh O'kennedy
Chief Scientific Officer, Executive Director
Ian Ford
Company Secretary, Executive Director
Frederic Boned
Non-Executive Director
株価売上高倍率（過去12カ月） | -- |
|---|---|
株価売上高倍率（過去12カ月） | 31.22 |
株価純資産倍率（四半期） | 9.60 |
株価キャッシュフロー倍率 | -- |
総負債／総資本（四半期） | 0.00 |
長期負債／資本（四半期） | 0.00 |
投資利益率(過去12カ月） | -26.38 |
自己資本利益率（過去12カ月) | -37.93 |
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。